



Published in final edited form as:

Ann Rheum Dis. 2013 July ; 72(7): 1188–1193. doi:10.1136/annrheumdis-2012-202007.

The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study

Ada Man¹, Yanyan Zhu², Yuqing Zhang², Maureen Dubreuil¹, Young Hee Rho², Christine Peloquin², Robert W Simms¹, and Hyon K Choi^{1,2}

¹Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA

²The Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts, USA

Abstract

Objectives—To evaluate the risk of incident myocardial infarction (MI), stroke and peripheral vascular disease (PVD) in individuals with systemic sclerosis (SSc) in a general population context.

Methods—We conducted a cohort study using a UK primary care database containing records from 1986 to 2011. SSc diagnoses, outcomes and cardiovascular risk factors were identified from electronic medical records. We conducted two cohort analyses: (1) MI and stroke, and (2) PVD, excluding individuals with prevalent disease at baseline for each analysis. We estimated HRs comparing SSc with age-, sex- and entry time-matched comparison cohorts, adjusting for potential cardiovascular risk factors.

Results—Among 865 individuals with SSc (85.8% women, mean age 58.7 years), the incidence rates (IRs) of MI and stroke were 4.4 and 4.8 per 1000 person-years (PY), versus 2.5 and 2.5 per 1000 PY in the comparison cohort. The corresponding adjusted HRs were 1.80 (95% CI 1.07 to 3.05) for MI and 2.61 (95% CI 1.54 to 4.44) for stroke. Among 858 individuals with SSc (85.3% female, mean age 58.9 years), the IR of PVD was 7.6 per 1000 PY versus 1.9 per 1000 PY in the comparison cohort, with an adjusted HR of 4.35 (95% CI 2.74 to 6.93).

Conclusions—These findings provide the first general population-based evidence that SSc is associated with an increased risk of developing MI, stroke and PVD. Further insight into disease mechanisms, as well as how disease subtype, organ involvement and medication use may alter these increased risks, is needed.

Correspondence to: Dr Ada Man, Arthritis Center/Rheumatology, Boston, University School of Medicine, 72 East Concord Street, Evans, 501, Boston, Massachusetts, 02118, USA; adaman@bu.edu.

Additional supplementary files are published online only. To view these files please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2012-202007>).

Contributors All authors participated in the conception, design and analyses of the study. AM and HKC drafted the manuscript and are guarantors. All authors contributed to interpretation of the results.

Competing interests None.

Ethics approval This study was judged exempt by the Institutional Review Board at Boston Medical Centre, and was approved by the National Health Service Multicentre Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Introduction

An increased risk of premature atherosclerotic disease in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) has been well described in the recent literature.¹² Much of the association between autoimmune diseases and atherosclerosis is believed to occur through chronic inflammation.³⁴ Systemic sclerosis (SSc), a related autoimmune disease with a less prominent inflammatory component but significant vascular abnormalities,⁵ such as Raynaud's phenomenon and pulmonary hypertension, has been proposed to cause premature atherosclerosis as well.^{6–8}

Two meta-analyses of studies assessing subclinical atherosclerosis showed that SSc patients had significantly increased carotid intima-media thickness (IMT), indicating an increased atherosclerotic burden, as compared with controls.^{9,10} This increased mean difference in carotid IMT reported (0.11 mm) was between that of patients with RA (0.09 mm) and diabetes (0.13 mm).⁹ SSc has also been shown to be an independent risk factor for coronary calcification, another marker of atherosclerosis and predictor of future coronary events.^{11,12} Furthermore, a recent cross-sectional analysis reported an increased prevalence of coronary artery disease among SSc patients (referred from rheumatology practices) as compared with external population-based cohorts.¹³ However, whether these findings of subclinical atherosclerosis and cross-sectional associations translate to an increased future risk of cardiovascular disease (CVD) among individuals with SSc is unknown.

SSc is currently associated with the highest mortality among all the connective tissue diseases, with an estimated 10 year survival of 66–82%.^{14–16} With recent improvements in the treatment of renal crisis and pulmonary hypertension, patients with SSc are dying less from SSc related problems and more from non-SSc related causes, which now account for close to 50% of all SSc deaths.^{14,17} As CVD contributes significantly to this mortality burden, accounting for 20–30% of all SSc deaths,⁸ an accurate understanding of CVD risk is crucial to improving the overall outcomes of SSc. Therefore, to address these issues, we evaluated the future risk of developing incident myocardial infarctions (MIs), strokes and peripheral vascular disease (PVD) in individuals with SSc in a general population context.

Methods

Data source

The Health Improvement Network (THIN) is an electronic medical record database derived from general practices in the UK. Data on approximately 7.3 million patients are recorded by general practitioners (GPs) as part of patients' clinical records and sent anonymously to THIN. Since approximately 97% of the UK population is registered with a GP,¹⁸ THIN data are representative of the UK general population.¹⁹ THIN data include demographics, details from GP visits, diagnoses and comments from specialists' referrals and hospital admissions, prescriptions, laboratory tests and additional information including height, weight and smoking status. The Read classification is used to code diagnoses,²⁰ and a drug dictionary based on the Multilex classification is used to code drugs.²¹ GPs receive specific training and regular feedback for accurate data recording;²² quality of THIN data has been shown to

be high¹⁹ and valid for use in pharmacoepidemiological research.²³ This study was approved by the UK National Health Service Multicentre Research Ethics Committee.

Study design

We conducted two cohort analyses: (1) incident MIs and strokes, and (2) incident PVD, among individuals with SSc (SSc cohorts) as compared with age-, sex- and entry time-matched individuals without SSc (comparison cohorts) using data from THIN. These analyses were conducted separately because the aetiological factors that lead to MIs and strokes may differ from those that lead to PVD, particularly in SSc, where previous studies have suggested that the prevalence in SSc patients may be increased for the latter but not for the former.^{24,25}

For each individual with SSc, we matched up to 10 patients who have not had an SSc diagnosis at any time, based on age, sex and month/year of cohort entry. Our study spanned the period of 1 January 1986 through 30 September 2011. Follow-up began after the first diagnosis of SSc for the SSc cohorts, and the matched date (index date) in the comparison cohorts. For both SSc and comparison cohorts, age greater than 18 years and continuous enrolment in the database for at least 12 months prior to start of follow-up was required.²⁶ Individuals who had a record documenting a history of or occurrence of coronary artery or cerebrovascular events (MIs, unstable angina, strokes and coronary or carotid revascularisation procedures) prior to the start of follow-up were excluded from the outcome analyses of MIs and strokes. In the same manner, individuals who had PVD prior to the start of follow-up were excluded for the analysis of the PVD outcome. Patients were followed until they experienced the outcomes of interest, died, left the THIN database or the follow-up ended (30 September 2011), whichever came first.

Definition of SSc

For inclusion into the SSc cohorts, a list of diagnosis records was used to identify all patients with a diagnosis of SSc. These included 'scleroderma', 'systemic sclerosis', 'progressive systemic sclerosis', 'CREST', 'myopathy due to scleroderma' and 'lung disease due to systemic sclerosis'. Individuals identified by a record for 'scleroderma' were excluded if they also had a record for localised scleroderma (morphoea) (N=44). We performed a secondary analysis by excluding individuals in the SSc and comparison cohorts who also had a diagnosis record of SLE or RA on or after the index date (indicating possibly overlap features in the SSc cohorts), since SLE and RA are known to increase the risk of CVD.

The method of using codes (ICD-9) to identify SSc patients from a database has been successfully employed in another population-based US study, yielding an incidence rate of SSc that was similar to other validated US estimates in the literature.²⁷ Further support for the accuracy of SSc coding comes from a validation study of ICD-9 coding in an administrative database, where the specificity of SSc diagnosis was high, at 94.9% (95% CI 93.0 to 96.2).²⁸ Physicians' diagnosis records of SSc in THIN, as opposed to billing codes, are expected to be even more accurate since they can be made after sufficient information (ie, lab results and consultations) has been collected, and corrected if necessary. SSc, in

particular, being a disease with such distinct physical features and potentially grave prognostic implications for the patient, is expected to be accurately recorded.

Ascertainment of outcomes

An individual was considered to have had an MI or stroke at the first recording of any Read term synonymous with these diagnoses.^{29–32} Diagnosis records that specified angina, transient ischaemic attacks, haemorrhagic strokes,³³ or sudden deaths were not included. PVD was defined as the first recording of PVD or claudication; arterial thromboembolism, occlusion, bypass or angioplasty of the lower extremities; and ischaemia or amputation of the legs or feet.^{33,34} Diagnosis records that specified arterial disease of the upper extremities or toes were not included to minimise inadvertent inclusion of the consequences of Raynaud's phenomenon.

Assessment of covariates

Cardiovascular risk factors were assessed prior to the start of follow-up based on the presence of relevant codes. Medication use was defined by the presence of a prescription in the 12 months prior to the start of follow-up. Diabetes and hyperlipidaemia were defined by the presence of a diagnosis record or a prescription of medications specific for the treatment of these respective diseases.³⁵ Cardiovascular risk factors have been successfully used in previous analyses in THIN by confirming anticipated associations such as those among smoking and lung cancer;³⁶ and body mass index (BMI), diabetes, hypertension, hyperlipidaemia and MI.²³

Statistical analyses

We compared the baseline characteristics across the SSc and comparison cohorts. In the cohort for MI and stroke, we identified cases of MIs and strokes during follow-up and calculated person-years (PY) to estimate incidence rates (IRs), both individually and as a composite outcome (ie, MI or stroke). We performed the same analysis in the cohort for PVD events and estimated IRs for PVD. We estimated the cumulative incidence of each event accounting for the competing risk of death³⁷ by using the SAS macro CUMINCID and graphically presented these results. We employed Cox proportional hazard regression models to assess multivariable HRs after stratifying by matched variables (age, sex and time of cohort entry). We imputed missing values for BMI and smoking using IVEware for SAS, V.9.2 (SAS Institute, Cary, North Carolina, USA).³⁸ We imputed five datasets and then combined estimates from these datasets.³⁹ Our multivariable analyses were adjusted for BMI (WHO categories, in kg/m²), smoking (never, past, and current), hypertension, diabetes, hyperlipidaemia and use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs) and oral glucocorticoids. Atrial fibrillation was adjusted for in the analysis of stroke and PVD because it is a risk factor for these outcomes.^{40,41} For all HRs, we calculated 95% CI. All p values were two-sided.

Results

Myocardial infarction and stroke

From 39 782 608 PY of follow-up in the THIN, 915 individuals with a first recorded diagnosis of SSc were identified. After exclusion of individuals with prior coronary artery and cerebrovascular events, 865 individuals with SSc (85.8% women, mean age 58.7 years) were included in the cohort analysis for MI and stroke. The baseline characteristics of the study cohorts for this analysis are shown in table 1. The SSc cohort had lower frequencies of overweight and obese status, more frequent past smoking status, and more frequent use of aspirin, NSAIDs and oral glucocorticoids.

The mean follow-up time was 5.2 years in the SSc cohort and 6.0 years in the comparison cohort. In the SSc cohort, new diagnoses of MI and stroke occurred in 20 and 22 individuals over 4557 and 4555 PY of follow-up, respectively (table 2). SSc was associated with an increased risk of MI and stroke. Relative to the comparison cohorts, the age-, sex- and entry time-matched HRs were 1.97 (95% CI 1.21 to 3.22) for MI and 2.56 (95% CI 1.58 to 4.14) for stroke. After adjusting for BMI, smoking, hypertension, diabetes, hyperlipidaemia, aspirin use and atrial fibrillation (for the stroke outcome only), the HR for MI was attenuated slightly, but not for stroke. After further adjustment for NSAID and oral glucocorticoid use, the HRs were 1.80 (95% CI 1.07 to 3.05) for MI and 2.61 (95% CI 1.54 to 4.44) for stroke. When we excluded individuals with SLE or RA diagnoses on or after the index date, the final adjusted HR was 1.93 (95% CI 1.12 to 3.33) for MI and 2.57 (95% CI 1.50 to 4.42) for stroke (see online supplementary table S1).

Peripheral vascular disease

In our analysis for PVD, 858 individuals with SSc (85.3% women, mean age 58.9 years) were included after exclusion of individuals with prior PVD. The baseline characteristics of the SSc and comparison cohorts were similar to those for the MI and stroke analysis (see online supplementary table S2). The mean follow-up time was 5.2 years in the SSc cohort and 5.9 years in the comparison cohort. In the SSc cohort, a new diagnosis of PVD occurred in 34 individuals over 4462 PY of follow-up (table 3). Relative to the comparison cohort, the age-, sex- and entry time-matched HR for PVD was 4.57 (95% CI 2.99 to 7.01). After adjusting for BMI, smoking, hypertension, diabetes, hyperlipidaemia, aspirin use and atrial fibrillation, this HR remained similar. After further adjustment for NSAID and oral glucocorticoid use, the HR was slightly reduced to 4.35 (95% CI 2.74 to 6.93). When we excluded individuals with SLE or RA diagnoses on or after the index date, the final adjusted HR was 4.88 (95% CI 3.00 to 7.94) (see online supplementary table S3).

Discussion

In this population-based cohort of patients with SSc, the risks of incident MI and stroke were increased approximately two-fold compared with those without SSc (figure 1), with the risk of stroke being greater than that of MI. Individuals with SSc also had a four-fold increased risk of PVD (figure 2). These associations persisted after adjustment for known and suspected cardiovascular risk factors, and also did not change materially after excluding

individuals with possibly SLE or RA overlap. These findings provide the first general population-based evidence that SSc is associated with an increased risk of developing MI, stroke, and PVD, and shed light on corresponding risk magnitudes associated with these CVD outcomes.

Many studies have examined for subclinical radiographic evidence of atherosclerosis (ie, carotid IMT, brachial artery flow mediated vasodilation, intracerebral and coronary calcification on CT) in SSc. A systematic review of such studies concluded that the prevalence of atherosclerosis was increased in all vessels studied in individuals with SSc.⁹ The data were most robust for carotid atherosclerosis identified by ultrasound, which has been shown in the general population to confer an increased risk of coronary artery disease, strokes and death.⁴² The results of our study expand upon these findings of subclinical atherosclerosis and provide support that the risk of clinically relevant cardiovascular events in SSc is increased as well.

Our findings are in general agreement with studies that have examined prevalences of CVD in individuals with and without SSc. For example, a cross-sectional study of 31 patients with limited cutaneous SSc versus 31 controls reported that the prevalences of coronary artery and cerebrovascular disease were increased 1.7 and 1.3 times, respectively.²⁴ However, these estimates were not statistically significant, likely due to the study's small sample size. Recently, another cross-sectional study compared the prevalences of coronary artery disease in the Australian Scleroderma Cohort Study with two external population-based cohorts, and found that SSc patients had over three times the prevalence of coronary artery disease.¹³ However, this study did not address stroke or PVD and the authors noted potential selection of patients with greater disease severity in their SSc cohort given their referral-based cohort recruitment.¹³

Several studies have also reported that PVD is more prevalent in SSc patients. Youssef and colleagues showed that PVD was six times as prevalent in SSc patients versus controls based on a chart review.²⁴ Our estimate is similar to another study that assessed intermittent claudication using a WHO questionnaire and found that the prevalence in SSc patients was 4.7 times as high compared with that of an external comparison cohort.⁴³ The same investigators subsequently performed a study using an ankle brachial pressure index (ABPI) cut-off of <0.9⁴⁴ to define PVD, showing that 17% of SSc patients had PVD compared with none in controls.⁴⁵

The increased risk of cardiovascular events found in our study may be due to atherosclerosis. Alternatively, these events may represent the effects of vasospasm, SSc specific vasculopathy, vasculitis, thrombosis or a combination of atherosclerotic and non-atherosclerotic factors. Furthermore, the mechanisms that lead to MI, stroke or PVD may be different in SSc, which may explain the higher observed risk for PVD, and slightly higher risk of stroke compared with MI. There are multiple possibilities as to why patients with SSc may develop increased atherosclerosis. Endothelial dysfunction, which is central to both SSc pathophysiology and atherogenesis,⁵⁴⁶ is associated with oxidative stress, resulting in reactive oxygen species (ROS) production.⁸ ROS oxidises low-density lipoprotein (LDL), and the subsequent consumption of oxidised LDL (ox-LDL) by monocytes is what leads to

the formation of atherogenic foam cells.³ Although foam cells have not been studied in SSc, circulating ox-LDL/ β 2-glycoprotein 1 complexes⁴⁷ and anti-ox-LDL antibodies may be elevated in SSc patients.⁴⁸ SSc patients may also have higher levels of atherogenic proinflammatory high-density lipoprotein (piHDL) and lipoprotein (a).¹²⁴⁹

By contrast, the prevalence of traditional CVD risk factors does not seem to be increased in SSc.¹³ Blood pressure has been shown to be similar between SSc and controls.⁵⁰ The frequencies of obesity, hyperlipidaemia, hypertension, and diabetes were not increased in SSc relative to comparison cohorts in our study, which is similar to what other studies of atherosclerotic disease in SSc patients have found.⁷¹¹¹³ Still, other disease-specific factors such as medication use and lack of exercise may be contributing factors to atherosclerotic disease. In this study, the HRs of MI and PVD were slightly decreased when NSAID and oral glucocorticoid use were adjusted for, indicating that either these medications were contributing to CVD risk, or that the indications for these medications (eg, prominent inflammatory features of SSc) at baseline were associated with CVD risk. The additional hemodynamic stresses conferred by pulmonary hypertension¹³ and interstitial lung disease, or potential stroke risk due to SSc related arrhythmias may also play a role.

The strengths of our study include the use of a large database that provided sufficient power to study a rare disease, SSc, in a general population context. At the same time, we had access to information on cardiovascular risk factors and outcomes over many years. Several limitations deserve comment. Uncertainty surrounding diagnostic accuracy is a potential concern in studies that identify cases from databases. However, THIN data, as opposed to administrative records, consist of medical records that physicians use for patient care, and thus the overall accuracy is expected to be higher, as reflected in many validation studies of important outcomes.³²⁵¹⁵² Misclassification of SSc in particular is expected to be rare given the distinct physical features of the disease, and the specificity of SSc diagnosis even in an administrative database has previously been shown to be high, at 94.9%.²⁸ In addition, the incidence rate of SSc found in our study of 23 per million PY is similar to several other estimates in the literature.¹⁷⁵³⁵⁴ While MIs and strokes are expected to be coded with high accuracy in THIN,³¹³² misclassification of PVD could occur if physicians mislabel a patient's Raynaud's symptoms as PVD despite our attempt to minimise this possibility. Nevertheless, it is reassuring that the risk estimates of PVD in SSc obtained from other studies using ABPI and questionnaires as discussed above were either higher than,⁴⁵ or similar,⁴³ respectively, to ours. We did not have access to disease specific information such as SSc subtype or organ involvement, which limited our ability to correlate such characteristics with the studied outcomes. As our study focused on the main links between SSc and the risk of CVD, these findings call for future studies aimed at identifying the risk factors for CVD, including disease specific features or medications among individuals with SSc. Furthermore, it would be valuable to examine extended aspects of CVD outcomes including their severity and consequences.

In conclusion, this general population-based cohort study suggests that SSc is associated with an increased risk of MI, stroke, and PVD. Our findings support the consideration of CVD disease prevention and surveillance in SSc patients, as CVD risk modification represents an opportunity to further reduce the morbidity and mortality of SSc.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding This work was supported in part by grants from the NIAMS (P60AR047785) and Boston University School of Medicine. AM is a recipient of the Roche Canada Scleroderma and Vasculitis Fellowship and the Gurmej Kaur Dhanda Scholarship award. The funding sources had no role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication.

References

1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum.* 2008; 59:1690–7. [PubMed: 19035419]
2. Hak AE, Karlson EW, Feskanich D, et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. *Arthritis Rheum.* 2009; 61:1396–402. [PubMed: 19790130]
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med.* 2005; 352:1685–95. [PubMed: 15843671]
4. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med.* 1999; 340:115–26. [PubMed: 9887164]
5. Fleming JN, Nash RA, Mahoney WM Jr, et al. Is scleroderma a vasculopathy? *Curr Rheumatol Rep.* 2009; 11:103–10. [PubMed: 19296882]
6. Ngian GS, Sahhar J, Wicks IP, et al. Cardiovascular disease in systemic sclerosis— an emerging association? *Arthritis Res Ther.* 2011; 13:237. [PubMed: 21888685]
7. Hettema ME, Bootsma H, Kallenberg CGM. Macrovascular disease and atherosclerosis in SSc. *Rheumatology (Oxford).* 2008; 47:578–83. [PubMed: 18321944]
8. Mok MY, Lau CS. The burden and measurement of cardiovascular disease in SSc. *Nat Rev Rheumatol.* 2010; 6:430–4. [PubMed: 20517296]
9. Au K, Singh MK, Bodukam V, et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. *Arthritis Rheum.* 2011; 63:2078–90. [PubMed: 21480189]
10. Tyrrell PN, Beyene J, Feldman BM, et al. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. *Arterioscler Thromb Vasc Biol.* 2010; 30:1014–26. [PubMed: 20150560]
11. Mok MY, Lau CS, Chiu SSH, et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. *Arthritis Rheum.* 2011; 63:1387–95. [PubMed: 21538320]
12. Khurma V, Meyer C, Park GS, et al. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. *Arthritis Rheum.* 2008; 59:591–7. [PubMed: 18383403]
13. Ngian GS, Sahhar J, Proudman SM, et al. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. *Ann Rheum Dis.* Published Online First: 24 April 2012. 10.1136/annrheumdis-2011-201176
14. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. *Ann Rheum Dis.* 2007; 66:940–4. [PubMed: 17329309]
15. Al-Dhafer FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. *Semin Arthritis Rheum.* 2010; 39:269–77. [PubMed: 18706680]
16. Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. *Rheumatology (Oxford).* 2012; 51:1017–26. [PubMed: 21900368]
17. Arias-Núñez MC, Llorca J, Vazquez-Rodríguez TR, et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. *Medicine (Baltimore).* 2008; 87:272–80. [PubMed: 18794710]

18. Simon C. Overview of the GP Contract. *InnovAiT*. 2008; 1:134–9.
19. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. *Inform Prim Care*. 2004; 12:171–7. [PubMed: 15606990]
20. Stuart-Buttle CD, Read JD, Sanderson HF, et al. A language of health in action: read codes, classifications and groupings. *Proc AMIA Annu Fall Symp*. 1996:75–9. [PubMed: 8947631]
21. <http://www.firstdatabank.co.uk/uploads/files/MultilexDDF%20for%20Primary%20Care.pdf> (accessed 17 Apr 2012)
22. Epic. THIN data from EPIC: a guide for researchers. London: EPIC; 2007.
23. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. *Pharmacoepidemiol Drug Saf*. 2007; 16:393–401. [PubMed: 17066486]
24. Youssef P, Brama T, Englert H, et al. Limited scleroderma is associated with increased prevalence of macrovascular disease. *J Rheumatol*. 1995; 22:469–72. [PubMed: 7783063]
25. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. *Am J Med*. 1969; 46:428–40. [PubMed: 5780367]
26. Lewis JD, Bilker WB, Weinstein RB, et al. The relationship between time since registration and measured incidence rates in the General Practice Research Database. *Pharmacoepidemiol Drug Saf*. 2005; 14:443–51. [PubMed: 15898131]
27. Frech T, Khanna D, Markewitz B, et al. Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study. *Arthritis Rheum*. 2010; 62:2109–16. [PubMed: 20506251]
28. Bernatsky S, Linehan T, Hanly JG. The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. *J Rheumatol*. 2011; 38:1612–16. [PubMed: 21532057]
29. Hammad TA, McAdams MA, Feight A, et al. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. *Pharmacoepidemiol Drug Saf*. 2008; 17:1197–201. [PubMed: 18985705]
30. García Rodríguez LA, Varas-Lorenzo C, Maguire A, et al. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. *Circulation*. 2004; 109:3000–6. [PubMed: 15197149]
31. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. *J Am Coll Cardiol*. 2008; 52:1628–36. [PubMed: 18992652]
32. Ruigomez A, Martin-Merino E, Garcia Rodriguez L. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). *Pharmacoepidemiol Drug Saf*. 2010; 19:579–85. [PubMed: 20131328]
33. Lee S, Shafe ACE, Cowie MR. UK Stroke Incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the general practice research database. *BMJ Open*. 2011; 1:e000269.
34. Warrington KJ, Jarpa EP, Crowson CS, et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. *Arthritis Res Ther*. 2009; 11:R50. [PubMed: 19335902]
35. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. *Br J Dermatol*. 2008; 159:1331–7. [PubMed: 18782318]
36. Toh S, Rodríguez LAG, Hernández-Díaz S. Use of antidepressants and risk of lung cancer. *Cancer Causes Control*. 2007; 18:1055–64. [PubMed: 17682831]
37. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med*. 1999; 18:695–706. [PubMed: 10204198]
38. Raghunathan TE, Lepkowski JM, Van Hoewyk J, et al. A multivariate technique for multiply imputing missing values using a sequence of regression models. *Survey Methodology*. 2001; 27:85–95.
39. Rubin, DB. Multiple imputation for nonresponse in surveys. Hoboken: John Wiley & Sons, Inc.; 2008.

40. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991; 22:983–8. [PubMed: 1866765]
41. Winkel TA, Hoeks SE, Schouten O, et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. *Eur J Vasc Endovasc Surg*. 2010; 40:9–16. [PubMed: 20385507]
42. Durward QJ, Ferguson GG, Barr HW. The natural history of asymptomatic carotid bifurcation plaques. *Stroke*. 1982; 13:459–64. [PubMed: 7101345]
43. Veale DJ, Collidge TA, Belch JJ. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. *Ann Rheum Dis*. 1995; 54:853–5. [PubMed: 7492228]
44. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. *Atherosclerosis*. 1991; 87:119–28. [PubMed: 1854359]
45. Ho M, Veale D, Eastmond C, et al. Macrovascular disease and systemic sclerosis. *Ann Rheum Dis*. 2000; 59:39–43. [PubMed: 10627425]
46. Hunt BJ. The endothelium in atherogenesis. *Lupus*. 2000; 9:189–93. [PubMed: 10805486]
47. Lopez LR, Simpson DF, Hurley BL, et al. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. *Ann N Y Acad Sci*. 2005; 1051:313–22. [PubMed: 16126973]
48. Herrick AL, Illingworth KJ, Hollis S, et al. Antibodies against oxidized low-density lipoproteins in systemic sclerosis. *Rheumatology (Oxford)*. 2001; 40:401–5. [PubMed: 11312377]
49. Lippi G, Caramaschi P, Montagnana M, et al. Lipoprotein (a) and the lipid profile in patients with systemic sclerosis. *Clin Chim Acta*. 2006; 364:345–8. [PubMed: 16111666]
50. Zakopoulos NA, Kotsis VT, Gialafos EJ, et al. Systemic sclerosis is not associated with clinical or ambulatory blood pressure. *Clin Exp Rheumatol*. 2003; 21:199–204. [PubMed: 12747274]
51. Seminara NM, Abuabara K, Shin DB, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. *Br J Dermatol*. 2011; 164:602–9. [PubMed: 21073449]
52. Meal A, Leonardi-Bee J, Smith C, et al. Validation of THIN data for non-melanoma skin cancer. *Qual Prim Care*. 2008; 16:49–52. [PubMed: 18700078]
53. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. *Arthritis Rheum*. 2003; 48:2246–55. [PubMed: 12905479]
54. Roberts-Thomson PJ, Jones M, Hakendorf P, et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. *Intern Med J*. 2001; 31:220–9. [PubMed: 11456035]




Figure 1. Cumulative incidence of myocardial infarction or stroke in 865 individuals with systemic sclerosis (SSc) as compared with 8643 age-, sex-, entry time-matched, non-SSc individuals. Estimates accounted for the competing risk of death. This figure is only reproduced in colour in the online version.




Figure 2. Cumulative incidence of peripheral vascular disease in 858 individuals with systemic sclerosis (SSc) as compared with 8580 age-, sex-, entry time-matched, non-SSc individuals. Estimates accounted for the competing risk of death. This figure is only reproduced in colour in the online version.

Table 1
Characteristics of systemic sclerosis (SSc) and comparison cohort at baseline[†]

Variable	SSc N=865	Non-SSc N=8643	p Value
Age (mean years±SD)	58.7±13.8	58.7±13.8	0.97
Female	742 (85.8%)	7416 (85.8%)	0.99
Body mass index (kg/m ²)			
<25.0	366 (42.3%)	2886 (33.4%)	<0.001*
25.0–29.9	204 (23.5%)	2379 (27.5%)	
30.0–34.9	91 (10.5%)	1054 (12.2%)	
35.0	37 (4.3%)	503 (5.8%)	
Unknown	167 (19.3%)	1821 (21.1%)	
Smoking status			
Never	459 (53.1%)	4587 (53.1%)	0.13*
Past	164 (19.0%)	1357 (15.7%)	
Current	161 (18.6%)	1599 (18.5%)	
Unknown	81 (9.4%)	1100 (12.7%)	
Hypertension	204 (23.6%)	1968 (22.8%)	0.59
Diabetes/diabetes medications	45 (5.2%)	398 (4.6%)	0.43
Hyperlipidaemia/lipid lowering medications	121 (14.0%)	1080 (12.5%)	0.21
Atrial fibrillation	18 (2.1%)	137 (1.6%)	0.27
Aspirin use [‡]	113 (13.1%)	647 (7.5%)	<0.001
Oral glucocorticoid use [‡]	141 (16.3%)	365 (4.2%)	<0.001
Nonsteroidal anti-inflammatory drug use [‡]	314 (36.3%)	1670 (19.3%)	<0.001

p Values are estimated by either Wilcoxon rank-sum test (continuous) or χ^2 test (categorical).

* p Values calculated by comparing non-missing data only.

[†] Cohorts used for the analysis of myocardial infarction and stroke. Cohort characteristics for the peripheral vascular disease analysis are shown in the supplementary table S2.

[‡] Prescription in the 12 months prior to cohort entry.

Table 2
HRs of incident myocardial infarction (MI) and stroke according to systemic sclerosis (SSc) status

	SSc N=865	Non-SSc N=8643
MI		
Cases, N	20	129
Incidence rate/1000 PY	4.4	2.5
Age-, sex-, entry time-matched HR (95% CI)	1.97 (1.21 to 3.22)	1.0
+ Cardiovascular risk factors adjusted HR (95% CI)*	1.88 (1.12 to 3.15)	1.0
+ NSAID and oral glucocorticoid adjusted HR (95% CI) [†]	1.80 (1.07 to 3.05)	1.0
Stroke		
Cases, N	22	129
Incidence rate/1000 PY	4.8	2.5
Age-, sex-, entry time-matched HR (95% CI)	2.56 (1.58 to 4.14)	1.0
+ Cardiovascular risk factors adjusted HR (95% CI) ^{*‡}	2.56 (1.54 to 4.26)	1.0
+ NSAID and oral glucocorticoid adjusted HR (95% CI) [†]	2.61 (1.54 to 4.44)	1.0
MI or stroke		
Cases, N	41	250
Incidence rate/1000 PY	9.1	4.9
Age-, sex-, entry time-matched HR (95% CI)	2.25 (1.59 to 3.18)	1.0
+ Cardiovascular risk factors adjusted HR (95% CI) ^{*‡}	2.24 (1.55 to 3.22)	1.0
+ NSAID and oral glucocorticoid adjusted HR (95% CI) [†]	2.16 (1.49 to 3.14)	1.0

* The cardiovascular risk factors adjusted model includes body mass index, smoking, hypertension, diabetes, hyperlipidaemia, and aspirin use.

[†] Further adjusted for all variables in the rows above.

[‡] Includes additional adjustment for atrial fibrillation.

NSAID, Nonsteroidal anti-inflammatory drug; PY, person-years.

Table 3
HRs of incident peripheral vascular disease according to systemic sclerosis (SSc) status

	SSc N=858	Non-SSc N=8580
Peripheral vascular disease *		
Cases, N	34	96
Incidence rate/1000 PY	7.6	1.9
Age-, sex-, entry time-matched HR (95% CI)	4.57 (2.99 to 7.01)	1.0
+ Cardiovascular risk factors adjusted HR (95% CI) [†]	4.65 (2.94 to 7.37)	1.0
+ NSAID and oral glucocorticoid adjusted HR (95% CI) [‡]	4.35 (2.74 to 6.93)	1.0

* Includes peripheral vascular disease or claudication; arterial thromboembolism, occlusion, bypass, or angioplasty of the lower extremities; and ischaemia or amputation of the legs or feet.

[†] The cardiovascular risk factors adjusted model includes body mass index, smoking, hypertension, diabetes, hyperlipidaemia, atrial fibrillation, and aspirin use.

[‡] Further adjusted for all variables in the rows above.

NSAID, Nonsteroidal anti-inflammatory drug; PY, person-years.